• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
VBLT

VBLT

Vascular Biogenics Ltd.

NASDAQHealthcareBiotechnologyIL

USD0.16

-0.01 (-8.77%)

Company Profile

CEO

Dror Harats

IPO Date

2014-10-01

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

IL

Market Metrics

Open

$0.17

Prev. Close

$0.17

Day Low

$0.15

Day High

$0.19

52W Low

$0.10

52W High

$0.32

Market Cap

$0.01B

Volume

5.38M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

12.0%

Avg Negative

7.6%

Avg Neutral

80.4%

News Feed

VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors

GlobeNewsWire·7/8/2021·↓ negative

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vascular Biogenics Ltd. - VBLT

PRNewsWire·6/16/2021·↓ negative

VBL Therapeutics: Feeling Bullish After VB-111 Clinical Trial Amendment

Seeking Alpha·6/10/2021
·↑ positive

VBL Therapeutics to Provide an Update on the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewsWire·5/20/2021·↑ positive

Vascular Biogenics' (VBLT) CEO Dror Harats on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/11/2021·↓ negative

Vascular Biogenics (VBLT) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research·5/11/2021·↑ positive

Vascular Biogenics's Earnings: A Preview

Benzinga·5/10/2021·↓ negative

Vascular Biogenics Ltd. Closes Public Offering of Ordinary Shares and Pre-Funded Warrants

GlobeNewsWire·4/14/2021·↑ positive

Vascular Biogenics Ltd. Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

GlobeNewsWire·4/8/2021·↑ positive

VBL Therapeutics to Host Virtual R&D Day on April 6

GlobeNewsWire·3/30/2021·↑ positive